Narrow Therapeutic Window of Ribavirin as an Inhibitor of Nitric Oxide Synthesis is Broadened by Macromolecular Prodrugs

Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerab...

Full description

Saved in:
Bibliographic Details
Published inBiomacromolecules Vol. 14; no. 11; pp. 3916 - 3926
Main Authors Wohl, Benjamin M, Smith, Anton A. A, Kryger, Mille B. L, Zelikin, Alexander N
Format Journal Article
LanguageEnglish
Published Washington, DC American Chemical Society 11.11.2013
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerably lessened by unfavorable pharmacokinetics. This interdisciplinary study contributes to the understanding of intracellular effects exerted by RBV and presents a successful design of macromolecular prodrugs of RBV to achieve a safer treatment. Specifically, we demonstrate that RBV exhibits a pronounced anti-inflammatory activity in cultured macrophages as is evidenced by a 2-fold decrease in the levels of produced nitric oxide achieved using a clinically relevant concentration of this drug. However, this effect was characterized by a rather narrow therapeutic window with experimental values of EC50 and IC50 being 7 and 19 μM, respectively. Macromolecular prodrugs were obtained using an acrylate derivative of RBV, RAFT polymerization technique, and N-vinyl pyrrolidone as a partner monomer. The synthesized polymers were characterized with uniform molecular weights, relatively narrow polydispersities, and gradually increasing content of RBV. The resulting polymer therapeutics were effective in delivering their payload to the cultured macrophages and afforded a significantly wider therapeutic window, as much as >1000 μM (18-fold in relative values). Taken together, this work contributes significantly to the development of safer methods for delivery of RBV, as well as understanding the mechanism of action and origins of the side effects of this broad-spectrum antiviral agent.
AbstractList Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerably lessened by unfavorable pharmacokinetics. This interdisciplinary study contributes to the understanding of intracellular effects exerted by RBV and presents a successful design of macromolecular prodrugs of RBV to achieve a safer treatment. Specifically, we demonstrate that RBV exhibits a pronounced anti-inflammatory activity in cultured macrophages as is evidenced by a 2-fold decrease in the levels of produced nitric oxide achieved using a clinically relevant concentration of this drug. However, this effect was characterized by a rather narrow therapeutic window with experimental values of EC sub(50) and IC sub(50) being 7 and 19 mu M, respectively. Macromolecular prodrugs were obtained using an acrylate derivative of RBV, RAFT polymerization technique, and N-vinyl pyrrolidone as a partner monomer. The synthesized polymers were characterized with uniform molecular weights, relatively narrow polydispersities, and gradually increasing content of RBV. The resulting polymer therapeutics were effective in delivering their payload to the cultured macrophages and afforded a significantly wider therapeutic window, as much as >1000 mu M (18-fold in relative values). Taken together, this work contributes significantly to the development of safer methods for delivery of RBV, as well as understanding the mechanism of action and origins of the side effects of this broad-spectrum antiviral agent.
Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerably lessened by unfavorable pharmacokinetics. This interdisciplinary study contributes to the understanding of intracellular effects exerted by RBV and presents a successful design of macromolecular prodrugs of RBV to achieve a safer treatment. Specifically, we demonstrate that RBV exhibits a pronounced anti-inflammatory activity in cultured macrophages as is evidenced by a 2-fold decrease in the levels of produced nitric oxide achieved using a clinically relevant concentration of this drug. However, this effect was characterized by a rather narrow therapeutic window with experimental values of EC50 and IC50 being 7 and 19 μM, respectively. Macromolecular prodrugs were obtained using an acrylate derivative of RBV, RAFT polymerization technique, and N-vinyl pyrrolidone as a partner monomer. The synthesized polymers were characterized with uniform molecular weights, relatively narrow polydispersities, and gradually increasing content of RBV. The resulting polymer therapeutics were effective in delivering their payload to the cultured macrophages and afforded a significantly wider therapeutic window, as much as >1000 μM (18-fold in relative values). Taken together, this work contributes significantly to the development of safer methods for delivery of RBV, as well as understanding the mechanism of action and origins of the side effects of this broad-spectrum antiviral agent.
Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerably lessened by unfavorable pharmacokinetics. This interdisciplinary study contributes to the understanding of intracellular effects exerted by RBV and presents a successful design of macromolecular prodrugs of RBV to achieve a safer treatment. Specifically, we demonstrate that RBV exhibits a pronounced anti-inflammatory activity in cultured macrophages as is evidenced by a 2-fold decrease in the levels of produced nitric oxide achieved using a clinically relevant concentration of this drug. However, this effect was characterized by a rather narrow therapeutic window with experimental values of EC₅₀ and IC₅₀ being 7 and 19 μM, respectively. Macromolecular prodrugs were obtained using an acrylate derivative of RBV, RAFT polymerization technique, and N-vinyl pyrrolidone as a partner monomer. The synthesized polymers were characterized with uniform molecular weights, relatively narrow polydispersities, and gradually increasing content of RBV. The resulting polymer therapeutics were effective in delivering their payload to the cultured macrophages and afforded a significantly wider therapeutic window, as much as >1000 μM (18-fold in relative values). Taken together, this work contributes significantly to the development of safer methods for delivery of RBV, as well as understanding the mechanism of action and origins of the side effects of this broad-spectrum antiviral agent.
Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerably lessened by unfavorable pharmacokinetics. This interdisciplinary study contributes to the understanding of intracellular effects exerted by RBV and presents a successful design of macromolecular prodrugs of RBV to achieve a safer treatment. Specifically, we demonstrate that RBV exhibits a pronounced anti-inflammatory activity in cultured macrophages as is evidenced by a 2-fold decrease in the levels of produced nitric oxide achieved using a clinically relevant concentration of this drug. However, this effect was characterized by a rather narrow therapeutic window with experimental values of EC50 and IC50 being 7 and 19 μM, respectively. Macromolecular prodrugs were obtained using an acrylate derivative of RBV, RAFT polymerization technique, and N-vinyl pyrrolidone as a partner monomer. The synthesized polymers were characterized with uniform molecular weights, relatively narrow polydispersities, and gradually increasing content of RBV. The resulting polymer therapeutics were effective in delivering their payload to the cultured macrophages and afforded a significantly wider therapeutic window, as much as >1000 μM (18-fold in relative values). Taken together, this work contributes significantly to the development of safer methods for delivery of RBV, as well as understanding the mechanism of action and origins of the side effects of this broad-spectrum antiviral agent.Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerably lessened by unfavorable pharmacokinetics. This interdisciplinary study contributes to the understanding of intracellular effects exerted by RBV and presents a successful design of macromolecular prodrugs of RBV to achieve a safer treatment. Specifically, we demonstrate that RBV exhibits a pronounced anti-inflammatory activity in cultured macrophages as is evidenced by a 2-fold decrease in the levels of produced nitric oxide achieved using a clinically relevant concentration of this drug. However, this effect was characterized by a rather narrow therapeutic window with experimental values of EC50 and IC50 being 7 and 19 μM, respectively. Macromolecular prodrugs were obtained using an acrylate derivative of RBV, RAFT polymerization technique, and N-vinyl pyrrolidone as a partner monomer. The synthesized polymers were characterized with uniform molecular weights, relatively narrow polydispersities, and gradually increasing content of RBV. The resulting polymer therapeutics were effective in delivering their payload to the cultured macrophages and afforded a significantly wider therapeutic window, as much as >1000 μM (18-fold in relative values). Taken together, this work contributes significantly to the development of safer methods for delivery of RBV, as well as understanding the mechanism of action and origins of the side effects of this broad-spectrum antiviral agent.
Author Kryger, Mille B. L
Smith, Anton A. A
Wohl, Benjamin M
Zelikin, Alexander N
AuthorAffiliation Department of Chemistry
Aarhus University
iNano Interdisciplinary Nanoscience Centre
AuthorAffiliation_xml – name: Department of Chemistry
– name: iNano Interdisciplinary Nanoscience Centre
– name: Aarhus University
Author_xml – sequence: 1
  givenname: Benjamin M
  surname: Wohl
  fullname: Wohl, Benjamin M
– sequence: 2
  givenname: Anton A. A
  surname: Smith
  fullname: Smith, Anton A. A
– sequence: 3
  givenname: Mille B. L
  surname: Kryger
  fullname: Kryger, Mille B. L
– sequence: 4
  givenname: Alexander N
  surname: Zelikin
  fullname: Zelikin, Alexander N
  email: zelikin@chem.au.dk
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27948520$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/24156371$$D View this record in MEDLINE/PubMed
BookMark eNqN0ltrFTEQAOAgLfaiD_4ByYugD9smu5PdzaMWL4XailZ8XGaTWU_KbnJMdrXn35vaUwUpKAQSki_DMDMHbMcHT4w9keJIilIe9xMIKaBND9i-VGVdQC3KnV9nVTSNbvbYQUpXQghdgXrI9kqQqq4auc-uzzHG8INfrijimpbZGf7FeZuvwsA_uh6_u-g8x8TR81O_cr2bQ7x5PHdzzPri2lninzZ-XlFyief1Kga05MnyfsPfo4lhCiOZZcTIP8Rg4_I1PWK7A46JHm_3Q_b5zevLk3fF2cXb05OXZwWClHNhtTW210pqIVuDSg2qlY1VtkJb9TQgtrIlodp2AE01gCQCXdelsgL0ANUhe34bdx3Dt4XS3E0uGRpH9BSW1JW5Kgqqstb_pLmcAELV8B8UVM63qqHN9OmWLv1EtltHN2HcdHc9yODZFmAyOA4RvXHpj2s0tKoU2R3fulzPlCINnXEzzi74OaIbOym6m2nofk9D_vHirx93Qe-z2yzQpO4qLNHnrtzjfgK557-H
CitedBy_id crossref_primary_10_1038_s41598_020_66944_4
crossref_primary_10_1371_journal_pntd_0010289
crossref_primary_10_1016_j_tetasy_2017_05_003
crossref_primary_10_1039_C4PY00624K
crossref_primary_10_1016_j_mtadv_2021_100140
crossref_primary_10_1002_adhm_201300637
crossref_primary_10_1002_adhm_201400307
crossref_primary_10_1002_adfm_201304312
crossref_primary_10_1080_15257770_2020_1723624
crossref_primary_10_3390_ph17050644
crossref_primary_10_1039_C5SC03257A
crossref_primary_10_3390_molecules22101736
crossref_primary_10_1016_j_jconrel_2015_04_016
crossref_primary_10_1016_j_tips_2015_05_001
crossref_primary_10_1039_C4SC02754J
crossref_primary_10_1155_2015_923614
crossref_primary_10_1016_j_jconrel_2014_09_032
crossref_primary_10_3390_molecules27072337
crossref_primary_10_1021_acs_molpharmaceut_6b00826
crossref_primary_10_1039_C5CC08011H
crossref_primary_10_1039_C4DT03609C
crossref_primary_10_1016_j_apmt_2020_100887
crossref_primary_10_3390_polym14040701
Cites_doi 10.1002/cmdc.201000352
10.1002/hep.21072
10.1016/S0006-2952(97)00223-2
10.1021/bm901129x
10.1177/109158189801700408
10.1021/cr9001403
10.1016/j.jconrel.2011.03.028
10.1038/nrd2468
10.1002/hep.1840360730
10.1016/j.ijbiomac.2012.02.019
10.3851/IMP1609
10.1093/clinids/12.6.1139
10.1016/j.dld.2010.10.007
10.1128/AAC.30.2.201
10.1208/s12249-008-9122-0
10.1021/nn204319b
10.1097/COH.0b013e32834b87f8
10.1053/he.2000.5789
10.1039/c3cc00315a
10.1016/j.ejphar.2005.11.037
10.1038/nrd703
10.1039/b904456f
10.3945/jn.108.100495
10.1016/j.polymer.2008.09.006
10.1007/s13277-010-0019-7
10.1002/mabi.200800163
10.1055/s-2006-947298
10.1016/S0021-9258(18)31375-9
10.1111/j.1478-3231.2008.01896.x
10.1038/nrd937
10.1021/nn700063w
10.1016/S1476-5586(03)80011-8
10.1016/0041-008X(84)90138-8
10.1016/S0169-409X(99)00024-1
10.1002/mabi.201300244
10.1517/14656560903580001
10.1002/pola.22606
10.1096/fj.06-6779com
10.1002/app.27680
10.1021/bc040241m
10.1038/nature04082
10.1295/polymj.30.31
10.1016/S0973-6883(12)60090-5
10.1021/bm700498j
10.1073/pnas.70.4.1174
10.1016/S0031-6997(25)06663-3
10.1016/j.colsurfb.2009.05.023
10.3109/10717544.2010.536272
10.1038/sj.cdd.4401115
10.1038/nrd1088
10.1016/j.biomaterials.2003.10.003
10.1016/S0039-9140(01)00323-X
10.1191/0961203305LU2109OA
10.1159/000050085
10.1002/pola.23479
10.1126/science.177.4050.705
10.1055/s-2004-832928
10.1021/jm010969d
ContentType Journal Article
Copyright Copyright © 2013 American Chemical Society
2015 INIST-CNRS
Copyright_xml – notice: Copyright © 2013 American Chemical Society
– notice: 2015 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7QO
8FD
FR3
P64
7S9
L.6
DOI 10.1021/bm401048s
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Biotechnology Research Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Biotechnology and BioEngineering Abstracts
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList Engineering Research Database

MEDLINE
AGRICOLA
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Applied Sciences
EISSN 1526-4602
EndPage 3926
ExternalDocumentID 24156371
27948520
10_1021_bm401048s
b336804221
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
02
23N
4.4
53G
55A
5GY
7~N
AABXI
ABFLS
ABMVS
ABPTK
ABUCX
ACGFS
ACS
AEESW
AENEX
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
CS3
DU5
EBS
ED
ED~
EJD
F5P
GNL
IH9
JG
JG~
LG6
P2P
RNS
ROL
RSW
TN5
UI2
VF5
VG9
W1F
X
XKZ
---
-~X
5VS
AAHBH
AAYXX
ABBLG
ABJNI
ABLBI
ABQRX
ADHLV
AHGAQ
BAANH
CITATION
CUPRZ
GGK
ZCA
~02
AFFNX
IHE
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7QO
8FD
FR3
P64
7S9
L.6
ID FETCH-LOGICAL-a411t-d9dcdb9519018ca55f5817d5d3ad3befaa818e0588f49e6441ee496625d049f43
IEDL.DBID ACS
ISSN 1525-7797
1526-4602
IngestDate Thu Jul 10 22:43:06 EDT 2025
Fri Jul 11 15:35:53 EDT 2025
Fri Jul 11 07:28:35 EDT 2025
Mon Jul 21 05:55:41 EDT 2025
Wed Apr 02 07:25:25 EDT 2025
Thu Apr 24 23:08:12 EDT 2025
Sun Jul 06 05:03:54 EDT 2025
Thu Aug 27 13:42:22 EDT 2020
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords Biological properties
Triazole derivative copolymer
Control release polymer
Antiinflammatory agent
Red blood cell
Cytotoxicity
Drug carrier
Prodrug
Experimental study
Biological activity
Ribavirin
Monodispersed polymer
Chain transfer
Hepatocyte
Activity concentration relation
Nitric oxide
Preparation
Pyrrolidone(vinyl) copolymer
Antiviral
Acrylate copolymer
Radical copolymerization
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a411t-d9dcdb9519018ca55f5817d5d3ad3befaa818e0588f49e6441ee496625d049f43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 24156371
PQID 1450183648
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_2000543269
proquest_miscellaneous_1524405649
proquest_miscellaneous_1450183648
pubmed_primary_24156371
pascalfrancis_primary_27948520
crossref_citationtrail_10_1021_bm401048s
crossref_primary_10_1021_bm401048s
acs_journals_10_1021_bm401048s
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
XKZ
7~N
VG9
W1F
ACS
AEESW
AFEFF
ABMVS
ABUCX
IH9
AQSVZ
ED~
UI2
PublicationCentury 2000
PublicationDate 2013-11-11
PublicationDateYYYYMMDD 2013-11-11
PublicationDate_xml – month: 11
  year: 2013
  text: 2013-11-11
  day: 11
PublicationDecade 2010
PublicationPlace Washington, DC
PublicationPlace_xml – name: Washington, DC
– name: United States
PublicationTitle Biomacromolecules
PublicationTitleAlternate Biomacromolecules
PublicationYear 2013
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References Sharma P. (ref3/cit3) 2006; 26
De Clercq E. (ref19/cit19) 2002; 1
Moorcroft M. J. (ref48/cit48) 2001; 54
Nair B. (ref43/cit43) 1998; 17
Levy G. A. (ref38/cit38) 2006; 43
Oberoi H. S. (ref62/cit62) 2011; 153
Jain M. K. (ref11/cit11) 2010; 11
Lavignac N. (ref59/cit59) 2009; 9
Li X. (ref35/cit35) 2008; 49
Kanuri G. (ref49/cit49) 2009; 139
Gilbert B. E. (ref15/cit15) 1986; 30
Streeter D. G. (ref22/cit22) 1973; 70
Boyer C. (ref45/cit45) 2009; 109
Nielsen A. L. (ref54/cit54) 2009; 73
ref2/cit2
Brochot E. (ref14/cit14) 2010; 15
Li X. (ref34/cit34) 2008; 108
Neeraj A. (ref36/cit36) 2011; 18
Di Stefano G. (ref41/cit41) 1997; 29
Wannachaiyasit S. (ref30/cit30) 2008; 9
Marletta M. A. (ref21/cit21) 1993; 268
Tsubota A. (ref51/cit51) 2002; 45
Rautio J. (ref53/cit53) 2008; 7
Zelikin A. N. (ref47/cit47) 2007; 8
ref42/cit42
Chang C.-W. (ref58/cit58) 2009; 24
Moncada S. (ref1/cit1) 1991; 43
Feld J. J. (ref17/cit17) 2005; 436
De Franceschi L. (ref12/cit12) 2000; 31
Shimoni O. (ref46/cit46) 2012; 6
Patterson J. L. (ref10/cit10) 1990; 12
Kast R. E. (ref23/cit23) 2003; 5
Allison A. C. (ref25/cit25) 2005; 14
Kryger M. B. L. (ref26/cit26) 2013; 49
Kovar L. (ref60/cit60) 2010; 31
Veronese F. M. (ref61/cit61) 2005; 16
Pissuwan D. (ref57/cit57) 2010; 11
Fried M. W. (ref7/cit7) 2002; 36
Michaelis M. (ref20/cit20) 2007; 21
Sidwell R. W. (ref9/cit9) 1972; 177
Vlieghe P. (ref37/cit37) 2002; 45
Fried M. W. (ref6/cit6) 2004; 24
Duncan R. (ref27/cit27) 2003; 2
Zelikin A. N. (ref56/cit56) 2007; 1
Di Stefano G. (ref40/cit40) 1997; 54
Majano P. L. (ref24/cit24) 2003; 10
Li X. (ref39/cit39) 2008; 46
Brillanti S. (ref8/cit8) 2011; 43
Kmoníčková E. (ref52/cit52) 2006; 530
Canonico P. G. (ref13/cit13) 1984; 74
Naik G. S. (ref16/cit16) 2012; 2
Gao Y. (ref33/cit33) 1998; 30
Tan S.-L. (ref5/cit5) 2002; 1
Giammona G. (ref32/cit32) 1999; 39
Li W. J. (ref29/cit29) 2012; 50
Dore G. J. (ref4/cit4) 2011; 6
Wan L. (ref31/cit31) 2006; 3
Li W. (ref28/cit28) 2010; 5
Kaneda Y. (ref44/cit44) 2004; 25
Hofmann W. P. (ref18/cit18) 2008; 28
Ren S. D. (ref55/cit55) 2009; 47
Markusic D. M. (ref50/cit50) 2009
References_xml – volume: 29
  start-page: 420
  issue: 5
  year: 1997
  ident: ref41/cit41
  publication-title: Italian J. Gastroenterol. Hepatol.
– volume: 5
  start-page: 1893
  issue: 11
  year: 2010
  ident: ref28/cit28
  publication-title: ChemMedChem
  doi: 10.1002/cmdc.201000352
– volume: 43
  start-page: 581
  issue: 3
  year: 2006
  ident: ref38/cit38
  publication-title: Hepatology
  doi: 10.1002/hep.21072
– volume: 54
  start-page: 357
  issue: 3
  year: 1997
  ident: ref40/cit40
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/S0006-2952(97)00223-2
– volume: 11
  start-page: 412
  issue: 2
  year: 2010
  ident: ref57/cit57
  publication-title: Biomacromolecules
  doi: 10.1021/bm901129x
– volume: 17
  start-page: 95
  issue: 4
  year: 1998
  ident: ref43/cit43
  publication-title: Int. J. Toxicol.
  doi: 10.1177/109158189801700408
– volume: 109
  start-page: 5402
  issue: 11
  year: 2009
  ident: ref45/cit45
  publication-title: Chem. Rev.
  doi: 10.1021/cr9001403
– volume: 153
  start-page: 64
  issue: 1
  year: 2011
  ident: ref62/cit62
  publication-title: J. Controlled Release
  doi: 10.1016/j.jconrel.2011.03.028
– volume: 7
  start-page: 255
  issue: 3
  year: 2008
  ident: ref53/cit53
  publication-title: Nat. Rev. Drug Discovery
  doi: 10.1038/nrd2468
– volume: 36
  start-page: s237
  issue: 5
  year: 2002
  ident: ref7/cit7
  publication-title: Hepatology
  doi: 10.1002/hep.1840360730
– volume: 50
  start-page: 974
  issue: 4
  year: 2012
  ident: ref29/cit29
  publication-title: Int. J. Biol. Macromol.
  doi: 10.1016/j.ijbiomac.2012.02.019
– volume: 15
  start-page: 687
  issue: 5
  year: 2010
  ident: ref14/cit14
  publication-title: Antiviral Ther.
  doi: 10.3851/IMP1609
– volume: 12
  start-page: 1139
  issue: 6
  year: 1990
  ident: ref10/cit10
  publication-title: Rev. Infect. Dis.
  doi: 10.1093/clinids/12.6.1139
– volume: 43
  start-page: 425
  year: 2011
  ident: ref8/cit8
  publication-title: Digest. Liver Dis.
  doi: 10.1016/j.dld.2010.10.007
– volume: 30
  start-page: 201
  issue: 2
  year: 1986
  ident: ref15/cit15
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.30.2.201
– volume: 9
  start-page: 840
  issue: 3
  year: 2008
  ident: ref30/cit30
  publication-title: AAPS PharmSciTech
  doi: 10.1208/s12249-008-9122-0
– volume: 6
  start-page: 1463
  issue: 2
  year: 2012
  ident: ref46/cit46
  publication-title: ACS Nano
  doi: 10.1021/nn204319b
– volume: 6
  start-page: 508
  year: 2011
  ident: ref4/cit4
  publication-title: Curr. Opin. HIV AIDS
  doi: 10.1097/COH.0b013e32834b87f8
– volume: 31
  start-page: 997
  issue: 4
  year: 2000
  ident: ref12/cit12
  publication-title: Hepatology
  doi: 10.1053/he.2000.5789
– volume: 49
  start-page: 2643
  issue: 26
  year: 2013
  ident: ref26/cit26
  publication-title: Chem. Commun.
  doi: 10.1039/c3cc00315a
– volume: 530
  start-page: 179
  issue: 1
  year: 2006
  ident: ref52/cit52
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2005.11.037
– volume: 1
  start-page: 13
  year: 2002
  ident: ref19/cit19
  publication-title: Nat. Rev. Drug Discovery
  doi: 10.1038/nrd703
– volume: 24
  start-page: 3580
  year: 2009
  ident: ref58/cit58
  publication-title: Chem. Commun.
  doi: 10.1039/b904456f
– volume: 139
  start-page: 482
  issue: 3
  year: 2009
  ident: ref49/cit49
  publication-title: J. Nutr.
  doi: 10.3945/jn.108.100495
– volume: 49
  start-page: 4769
  issue: 22
  year: 2008
  ident: ref35/cit35
  publication-title: Polymer
  doi: 10.1016/j.polymer.2008.09.006
– volume: 31
  start-page: 233
  issue: 4
  year: 2010
  ident: ref60/cit60
  publication-title: Tumor Biol.
  doi: 10.1007/s13277-010-0019-7
– volume: 9
  start-page: 480
  issue: 5
  year: 2009
  ident: ref59/cit59
  publication-title: Macromol. Biosci.
  doi: 10.1002/mabi.200800163
– volume: 26
  start-page: 285
  issue: 3
  year: 2006
  ident: ref3/cit3
  publication-title: Semin. Liver Dis.
  doi: 10.1055/s-2006-947298
– volume: 268
  start-page: 12231
  year: 1993
  ident: ref21/cit21
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(18)31375-9
– volume: 28
  start-page: 1332
  year: 2008
  ident: ref18/cit18
  publication-title: Liver Int.
  doi: 10.1111/j.1478-3231.2008.01896.x
– volume: 1
  start-page: 867
  year: 2002
  ident: ref5/cit5
  publication-title: Nat. Rev. Drug Discovery
  doi: 10.1038/nrd937
– volume: 1
  start-page: 63
  issue: 1
  year: 2007
  ident: ref56/cit56
  publication-title: ACS Nano
  doi: 10.1021/nn700063w
– volume: 5
  start-page: 3
  year: 2003
  ident: ref23/cit23
  publication-title: Neoplasia
  doi: 10.1016/S1476-5586(03)80011-8
– ident: ref2/cit2
– volume: 74
  start-page: 155
  issue: 2
  year: 1984
  ident: ref13/cit13
  publication-title: Toxicol. Appl. Pharmacol.
  doi: 10.1016/0041-008X(84)90138-8
– volume: 39
  start-page: 153
  issue: 1
  year: 1999
  ident: ref32/cit32
  publication-title: Adv. Drug Delivery Rev.
  doi: 10.1016/S0169-409X(99)00024-1
– ident: ref42/cit42
  doi: 10.1002/mabi.201300244
– volume: 11
  start-page: 673
  year: 2010
  ident: ref11/cit11
  publication-title: Expert Opin. Pharmacother.
  doi: 10.1517/14656560903580001
– volume: 46
  start-page: 2734
  issue: 8
  year: 2008
  ident: ref39/cit39
  publication-title: J. Polym. Sci., Polym. Chem.
  doi: 10.1002/pola.22606
– volume: 21
  start-page: 81
  year: 2007
  ident: ref20/cit20
  publication-title: FASEB J.
  doi: 10.1096/fj.06-6779com
– volume: 108
  start-page: 431
  issue: 1
  year: 2008
  ident: ref34/cit34
  publication-title: J. Appl. Polym. Sci.
  doi: 10.1002/app.27680
– volume: 16
  start-page: 775
  issue: 4
  year: 2005
  ident: ref61/cit61
  publication-title: Bioconjugate Chem.
  doi: 10.1021/bc040241m
– volume: 436
  start-page: 967
  year: 2005
  ident: ref17/cit17
  publication-title: Nature
  doi: 10.1038/nature04082
– volume: 3
  issue: 1
  year: 2006
  ident: ref31/cit31
  publication-title: AIDS Res. Ther.
– volume: 30
  start-page: 31
  issue: 1
  year: 1998
  ident: ref33/cit33
  publication-title: Polym. J.
  doi: 10.1295/polymj.30.31
– volume: 2
  start-page: 42
  issue: 1
  year: 2012
  ident: ref16/cit16
  publication-title: J. Clin. Exp. Hepatol.
  doi: 10.1016/S0973-6883(12)60090-5
– volume: 8
  start-page: 2950
  issue: 9
  year: 2007
  ident: ref47/cit47
  publication-title: Biomacromolecules
  doi: 10.1021/bm700498j
– volume: 70
  start-page: 1174
  issue: 4
  year: 1973
  ident: ref22/cit22
  publication-title: Proc. Natl. Acad. Sci. U.S.A.
  doi: 10.1073/pnas.70.4.1174
– volume: 43
  start-page: 109
  issue: 2
  year: 1991
  ident: ref1/cit1
  publication-title: Pharmacol. Rev.
  doi: 10.1016/S0031-6997(25)06663-3
– volume: 73
  start-page: 267
  issue: 2
  year: 2009
  ident: ref54/cit54
  publication-title: Colloids Surf., B
  doi: 10.1016/j.colsurfb.2009.05.023
– volume: 18
  start-page: 272
  issue: 4
  year: 2011
  ident: ref36/cit36
  publication-title: Drug Delivery
  doi: 10.3109/10717544.2010.536272
– volume: 10
  start-page: S13
  year: 2003
  ident: ref24/cit24
  publication-title: Cell Death Differ.
  doi: 10.1038/sj.cdd.4401115
– volume: 2
  start-page: 347
  issue: 5
  year: 2003
  ident: ref27/cit27
  publication-title: Nat. Rev. Drug Discovery
  doi: 10.1038/nrd1088
– volume: 25
  start-page: 3259
  issue: 16
  year: 2004
  ident: ref44/cit44
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2003.10.003
– start-page: 9
  year: 2009
  ident: ref50/cit50
  publication-title: BMC Biotechnol.
– volume: 54
  start-page: 785
  year: 2001
  ident: ref48/cit48
  publication-title: Talanta
  doi: 10.1016/S0039-9140(01)00323-X
– volume: 14
  start-page: s2
  year: 2005
  ident: ref25/cit25
  publication-title: Lupus
  doi: 10.1191/0961203305LU2109OA
– volume: 45
  start-page: 33
  year: 2002
  ident: ref51/cit51
  publication-title: Intervirology
  doi: 10.1159/000050085
– volume: 47
  start-page: 4267
  issue: 17
  year: 2009
  ident: ref55/cit55
  publication-title: J. Polym. Sci., Polym. Chem.
  doi: 10.1002/pola.23479
– volume: 177
  start-page: 705
  issue: 4050
  year: 1972
  ident: ref9/cit9
  publication-title: Science
  doi: 10.1126/science.177.4050.705
– volume: 24
  start-page: 47
  issue: 2
  year: 2004
  ident: ref6/cit6
  publication-title: Semin. Liver Dis.
  doi: 10.1055/s-2004-832928
– volume: 45
  start-page: 1275
  issue: 6
  year: 2002
  ident: ref37/cit37
  publication-title: J. Med. Chem.
  doi: 10.1021/jm010969d
SSID ssj0009345
Score 2.225066
Snippet Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success,...
SourceID proquest
pubmed
pascalfrancis
crossref
acs
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3916
SubjectTerms adverse effects
Animals
anti-inflammatory activity
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - chemical synthesis
Antiviral Agents - chemistry
Antiviral Agents - pharmacology
Applied sciences
Biological and medical sciences
Cell Survival - drug effects
Cells, Cultured
Dose-Response Relationship, Drug
Drug Design
drug therapy
drugs
Exact sciences and technology
Hep G2 Cells
Hepatitis C virus
Humans
inhibitory concentration 50
Macromolecular Substances - chemical synthesis
Macromolecular Substances - chemistry
Macromolecular Substances - pharmacology
macrophages
Macrophages - drug effects
Macrophages - metabolism
mechanism of action
median effective concentration
Medical sciences
Mice
Molecular Structure
molecular weight
nitric oxide
Nitric Oxide - biosynthesis
Organic polymers
pharmacokinetics
Pharmacology. Drug treatments
Physicochemistry of polymers
polymerization
polymers
Polymers with particular properties
Preparation, kinetics, thermodynamics, mechanism and catalysts
Prodrugs - chemical synthesis
Prodrugs - chemistry
Prodrugs - pharmacology
pyrrolidones
Ribavirin - chemistry
Ribavirin - pharmacology
Structure-Activity Relationship
Time Factors
Title Narrow Therapeutic Window of Ribavirin as an Inhibitor of Nitric Oxide Synthesis is Broadened by Macromolecular Prodrugs
URI http://dx.doi.org/10.1021/bm401048s
https://www.ncbi.nlm.nih.gov/pubmed/24156371
https://www.proquest.com/docview/1450183648
https://www.proquest.com/docview/1524405649
https://www.proquest.com/docview/2000543269
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1LT9wwELYoPbQSKn3CtrByH4deQuNX4hzRFgSV2FYFVG6RHdsQAVm02a2gv75jJ9ktgqVSTskkcuyx5xuN_X0IfdKKpNYXWbk1LOLUpZGKnYjiWGkiE2tpUJ47GCZ7x_zbiThZQh8XVPAp-aIvuc8ZZP0IPaaJTH2GtT04nDPrsqBE7HV8ACpmaUcf9O-rPvQU9a3Qs3KlaugF18hXLMaXIc7srqKv3WmdZnvJ-dZ0oreKP3fJGx_6hefoWYsz8XbjGC_Qkq1eoieDTt7tFboeBvpFfDQ_gIV_QYIOt0YO_yy1-l2OywqrGqsK71dnpYbJP_YPh6Wn9cffr0tj8eFNBRiyLmsMFyT1ChYya7C-wQcq7PVr5XfxD1iqx9PT-jU63t05GuxFrQxDpDghk8hkpjAakBhAB1koIZyQJDXCMGWYtk4pCPo2FlI6nlmPr6zlkEVRYSD9cJy9QcvVqLLrCMtE0kzQAjCX4sxmAWLCh5VxLJZa9lAfxilvp1Gdhwo5JfmsA3voczeEedGSmHstjYv7TD_MTK8a5o77jPq3_GBmSVNPm0PjHnrfOUYOA-SrKaqyoym0jXsuRJZw-YCNAPQEEJNni21ogM2AosFmrfG8eSt8es1S8vZ__fIOPaVep8PvTyQbaHkyntpNQEsT3Q-z5S_Odg2c
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1db9MwFLVgPAxpYnxTNopBPPCSLf5qnMep2tTBWhDrxN4iO7YhGqRT3aKNX8-1k7YMbYCUp-Qmcq6v7XN17XMQeqMVyWwosnJrWMKpyxKVOpGkqdJE9qylUXluOOoNTvi7U3Ha0uSEszDQCA9f8rGIv2IXILv6Ow-pg_S30R0AITQkWnv94xXBLouCxEHOBxBjni1YhH5_NaxApb-yAm2cKw_OcI2Kxc0wMy43B5uNblFsaNxlcrYzn-md8ucfHI7_9yf30b0WdeK9JkweoFu2fojW-wuxt0foYhTJGPF4dRwLf4Z0HW5NHP5UafWjmlY1Vh6rGh_WXysNU8E0PBxVgeQff7iojMXHlzUgSl95DBek-AqmNWuwvsRDFXf-tWK8-CNM3NP5F_8YnRzsj_uDpBVlSBQnZJaY3JRGAy4DICFLJYQTkmRGGKYM09YpBRDApkJKx3Mb0Ja1HHIqKgwkI46zJ2itntT2GcKyJ2kuaAkITHFm8wg44cPKOJZKLTuoC_4r2kHli1gvp6RYOrCD3i56sihbSvOgrPHtOtPXS9PzhsfjOqPulXBYWtIskOjQtINeLeKjgA4KtRVV28kc2sYDMyLrcfkXGwFYCgAnz2-2oRFEA6YGm6dNAK5aEZJtlpHn__LLS7Q-GA-PiqPD0fstdJcGBY-wc5Fso7XZdG5fAI6a6W4cQL8AZfgV_Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELZgSDAJ8XNA-VEM4oGXjNixG-dxKlQbsG5im9hbZMf2iIC0qlu08ddz56YtQxsg5Sm5RBf7bH-ns7-PkFdGs9xhkVU4myWC-zzRqZdJmmrDVM85HpXndoe97SPx_lget4kinoUBJwJ8KcQiPo7qsfUtwwB7Y74LTB9UuEquYbkOk62t_sGKZDeLosQo6QOoscgXTEK_v4qrUBXOrUI3xzpAg_i5ksXlUDMuOYPbZG_pbNxp8nVzNjWb1c8_eBz__2_ukFst-qRb83C5S6645h650V-Ivt0np8NIykgPV8ey6GdI2-HWyNNPtdE_6kndUB2obuhO86U2MCVM8OGwRrJ_undaW0cPzhpAlqEOFC5I9TVMb85Sc0Z3ddwB2Iry0n2YwCezk7BBjgbvDvvbSSvOkGjB2DSxha2sAXwGgEJVWkovFcuttJm2mXFea4ACLpVKeVE4RF3OCcituLSQlHiRPSBrzahxjwhVPcULyStAYlpkrojAEz6src9SZVSHdKENy3ZwhTLWzTkrlw3YIa8XvVlWLbU5Kmx8u8j05dJ0POfzuMioey4klpY8RzIdnnbIi0WMlNBBWGPRjRvNwDeBDIlZT6i_2EjAVAA8RXG5DY9gGrA12DycB-HKC0y6s5w9_le7PCfX998Oyo87ww9PyDpHIQ_cwMiekrXpZOaeAZyamm4cQ78AaNUYgA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Narrow+Therapeutic+Window+of+Ribavirin+as+an+Inhibitor+of+Nitric+Oxide+Synthesis+is+Broadened+by+Macromolecular+Prodrugs&rft.jtitle=Biomacromolecules&rft.au=Wohl%2C+Benjamin+M&rft.au=Smith%2C+Anton+A.+A&rft.au=Kryger%2C+Mille+B.+L&rft.au=Zelikin%2C+Alexander+N&rft.date=2013-11-11&rft.pub=American+Chemical+Society&rft.issn=1525-7797&rft.eissn=1526-4602&rft.volume=14&rft.issue=11&rft.spage=3916&rft.epage=3926&rft_id=info:doi/10.1021%2Fbm401048s&rft.externalDocID=b336804221
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1525-7797&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1525-7797&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1525-7797&client=summon